• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

钠-葡萄糖协同转运蛋白2抑制剂对合并糖尿病的非酒精性脂肪性肝病的影响：基于系列肝活检的初步前瞻性研究

Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies.

作者信息

Akuta Norio, Watanabe Chizuru, Kawamura Yusuke, Arase Yasuji, Saitoh Satoshi, Fujiyama Shunichiro, Sezaki Hitomi, Hosaka Tetsuya, Kobayashi Masahiro, Kobayashi Mariko, Suzuki Yoshiyuki, Suzuki Fumitaka, Ikeda Kenji, Kumada Hiromitsu

机构信息

Department of Hepatology Toranomon Hospital and Okinaka Memorial Institute for Medical Research Tokyo Japan.

Department of Endocrinology and Metabolism, Toranomon Hospital Tokyo Japan.

出版信息

Hepatol Commun. 2017 Feb 27;1(1):46-52. doi: 10.1002/hep4.1019. eCollection 2017 Feb.

DOI:10.1002/hep4.1019
PMID:29404432
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5747031/
Abstract

A prospective study based on serial liver biopsies was performed to investigate the efficacy of sodium-glucose cotransporter 2 inhibitor for nonalcoholic fatty liver disease complicated with type 2 diabetes mellitus. : Treatment for 24 weeks resulted in improvement in histopathologic features in all 5 patients. (Hepatology Communications 2017;1:46-52).

摘要

进行了一项基于系列肝活检的前瞻性研究，以调查钠-葡萄糖协同转运蛋白2抑制剂对合并2型糖尿病的非酒精性脂肪性肝病的疗效。：24周的治疗使所有5例患者的组织病理学特征得到改善。（《肝脏病学通讯》2017年；1：46 - 52）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bf/5747031/60a4771cbd24/HEP4-1-46-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bf/5747031/60a4771cbd24/HEP4-1-46-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bf/5747031/60a4771cbd24/HEP4-1-46-g001.jpg

相似文献

1
Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies.钠-葡萄糖协同转运蛋白2抑制剂对合并糖尿病的非酒精性脂肪性肝病的影响：基于系列肝活检的初步前瞻性研究
Hepatol Commun. 2017 Feb 27;1(1):46-52. doi: 10.1002/hep4.1019. eCollection 2017 Feb.
2
Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂对非酒精性脂肪性肝病合并糖尿病组织学特征及糖代谢的影响
Hepatol Res. 2019 May;49(5):531-539. doi: 10.1111/hepr.13304. Epub 2019 Feb 6.
3
Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.2型糖尿病合并非酒精性脂肪性肝病患者中，钠-葡萄糖协同转运蛋白2抑制剂与磺脲类药物的多效性作用及安全性的研究方案
Diabetes Ther. 2020 Feb;11(2):549-560. doi: 10.1007/s13300-020-00762-9. Epub 2020 Jan 20.
4
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂对日本非酒精性脂肪性肝病合并2型糖尿病患者肝功能检查的影响。
Hepatol Res. 2017 Sep;47(10):1072-1078. doi: 10.1111/hepr.12834. Epub 2016 Dec 7.
5
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.达格列净对2型糖尿病相关非酒精性脂肪性肝炎患者身体成分和肝功能检查的影响：一项前瞻性、开放标签、非对照研究。
Curr Ther Res Clin Exp. 2017 Jul 8;87:13-19. doi: 10.1016/j.curtheres.2017.07.002. eCollection 2017.
6
Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.钠-葡萄糖协同转运蛋白2抑制剂托格列净对肥胖和糖尿病小鼠二乙基亚硝胺诱导的肝脏肿瘤发生的预防作用
Oncotarget. 2017 Apr 6;8(35):58353-58363. doi: 10.18632/oncotarget.16874. eCollection 2017 Aug 29.
7
Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan.钠-葡萄糖协同转运蛋白2抑制剂对日本非酒精性脂肪性肝病合并2型糖尿病患者肾功能的影响。
Diagnostics (Basel). 2020 Feb 6;10(2):86. doi: 10.3390/diagnostics10020086.
8
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!新型抗糖尿病药物对非酒精性脂肪肝和脂肪性肝炎的影响：另辟蹊径！
Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28.
9
Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease.钠-葡萄糖共转运蛋白 2 抑制剂在非酒精性脂肪性肝病治疗中的作用。
World J Gastroenterol. 2019 Jul 28;25(28):3664-3668. doi: 10.3748/wjg.v25.i28.3664.
10
Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease.钠-葡萄糖协同转运蛋白2抑制剂在非酒精性脂肪性肝病管理中的兴起
World J Hepatol. 2019 Jul 27;11(7):562-573. doi: 10.4254/wjh.v11.i7.562.

引用本文的文献

1
Histopathological changes in two patients with hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease treated with pemafibrate: a serial liver biopsy study.使用匹伐他汀治疗的两名高甘油三酯血症和代谢功能障碍相关脂肪性肝病患者的组织病理学变化：一项肝脏活检系列研究
Clin J Gastroenterol. 2025 Jul 18. doi: 10.1007/s12328-025-02185-0.
2
Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.替尔泊肽对2型糖尿病合并代谢功能障碍相关脂肪性肝病患者的影响：一项回顾性队列研究
Cureus. 2025 May 8;17(5):e83712. doi: 10.7759/cureus.83712. eCollection 2025 May.
3

本文引用的文献

1
Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.循环miR-122对日本非酒精性脂肪性肝病组织学特征和肝细胞癌的影响
Hepatol Int. 2016 Jul;10(4):647-56. doi: 10.1007/s12072-016-9729-2. Epub 2016 Apr 13.
2
Appropriate use of virtual touch quantification and FibroScan M and XL probes according to the skin capsular distance.根据皮肤包膜距离适当使用虚拟触诊定量技术以及FibroScan M和XL探头。
J Gastroenterol. 2016 May;51(5):496-505. doi: 10.1007/s00535-015-1127-3. Epub 2015 Oct 13.
3
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Impact of Sodium-Glucose Co-Transporter Type-2 Inhibitors on Alanine Aminotransferase Levels in Type-2 Diabetes Patients Having Features of Nonalcoholic Fatty Liver Disease: A Retrospective Cohort Study in Pakistan.
2型钠-葡萄糖协同转运蛋白抑制剂对具有非酒精性脂肪性肝病特征的2型糖尿病患者丙氨酸氨基转移酶水平的影响：巴基斯坦的一项回顾性队列研究
Pak J Med Sci. 2024 Dec;40(11):2681-2688. doi: 10.12669/pjms.40.11.8900.
4
Dapagliflozin: A Promising Strategy to Combat Cisplatin-Induced Hepatotoxicity in Wistar Rats.达格列净：对抗顺铂诱导的Wistar大鼠肝毒性的一种有前景的策略。
Biology (Basel). 2024 Aug 29;13(9):672. doi: 10.3390/biology13090672.
5
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease.治疗代谢相关脂肪性肝病的现有和新型药物的综述。
Hepatol Int. 2024 Oct;18(Suppl 2):977-989. doi: 10.1007/s12072-024-10698-y. Epub 2024 Jun 8.
6
Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives.钠-葡萄糖协同转运蛋白2抑制剂与心脏病：当前观点
World J Cardiol. 2024 May 26;16(5):240-259. doi: 10.4330/wjc.v16.i5.240.
7
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂的系统和器官特异性抗炎作用。
Trends Endocrinol Metab. 2024 May;35(5):425-438. doi: 10.1016/j.tem.2024.02.003. Epub 2024 Feb 29.
8
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.抗糖尿病药物在非酒精性脂肪性肝病（NAFLD）中的作用。我们是否已经找到了圣杯？一篇叙述性综述。
Eur J Clin Pharmacol. 2024 Jan;80(1):127-150. doi: 10.1007/s00228-023-03586-1. Epub 2023 Nov 8.
9
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).非酒精性脂肪性肝病 (NAFLD) 的治疗进展。
Front Endocrinol (Lausanne). 2023 Jan 16;13:1087260. doi: 10.3389/fendo.2022.1087260. eCollection 2022.
10
O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease.O-糖基化修饰缓解非酒精性脂肪性肝病的进展。
Cells. 2022 Nov 16;11(22):3637. doi: 10.3390/cells11223637.
依帕格列净，一种 SGLT2 抑制剂，在胆碱缺乏 L-氨基酸定义饮食诱导的大鼠肝脂肪变性和纤维化中具有预防作用。
Eur J Pharmacol. 2015 May 5;754:19-24. doi: 10.1016/j.ejphar.2015.02.009. Epub 2015 Feb 19.
4
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.法尼醇X核受体配体奥贝胆酸治疗非肝硬化、非酒精性脂肪性肝炎（FLINT）：一项多中心、随机、安慰剂对照试验
Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7.
5
Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.非酒精性脂肪性肝病中的循环微小RNA特征：从血清非编码RNA到肝脏组织学及疾病发病机制
Gut. 2015 May;64(5):800-12. doi: 10.1136/gutjnl-2014-306996. Epub 2014 Jun 27.
6
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.肝活检及非侵入性诊断测试在非酒精性脂肪性肝病/非酒精性脂肪性肝炎诊断中的局限性
World J Gastroenterol. 2014 Jan 14;20(2):475-85. doi: 10.3748/wjg.v20.i2.475.
7
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.在二甲双胍控制不佳的 2 型糖尿病患者中，卡格列净对比格列美脲的疗效和安全性（CANTATA-SU）：一项随机、双盲、3 期非劣效性临床试验的 52 周结果。
Lancet. 2013 Sep 14;382(9896):941-50. doi: 10.1016/S0140-6736(13)60683-2. Epub 2013 Jul 12.
8
Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver.循环 microRNAs（miR-21、miR-34a、miR-122 和 miR-451）与非酒精性脂肪肝的关系。
Clin Chim Acta. 2013 Sep 23;424:99-103. doi: 10.1016/j.cca.2013.05.021. Epub 2013 May 30.
9
Determination of reliability criteria for liver stiffness evaluation by transient elastography.瞬时弹性成像技术评估肝脏硬度的可靠性标准测定。
Hepatology. 2013 Mar;57(3):1182-91. doi: 10.1002/hep.25993. Epub 2013 Feb 4.
10
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.卡格列净（钠-葡萄糖共转运蛋白 2 抑制剂）作为二线治疗药物与二甲双胍联用在 2 型糖尿病患者中的剂量范围效应。
Diabetes Care. 2012 Jun;35(6):1232-8. doi: 10.2337/dc11-1926. Epub 2012 Apr 9.